Treatment of anemia in low risk myelodysplastic syndromes with granulocyte–macrophage colony-stimulating factor plus recombinant human erythropoietin

T. Economopoulos; S. Mellou; E. Papageorgiou; Vasiliki Pappa; V. Kokkinou; Ε. Σταθοπούλου; Μαρία Παππά; S. Raptis

doi:10.1038/sj.leu.2401442

ScienceGate Book Chapters

JOURNAL ARTICLE

Treatment of anemia in low risk myelodysplastic syndromes with granulocyte–macrophage colony-stimulating factor plus recombinant human erythropoietin

T. Economopoulos S. Mellou E. Papageorgiou Vasiliki Pappa V. Kokkinou Ε. Σταθοπούλου Μαρία Παππά S. Raptis

Year: 1999 Journal: Leukemia Vol: 13 (7)Pages: 1009-1012 Publisher: Springer Nature

DOI: 10.1038/sj.leu.2401442

Get Full-Text PDF Get Analytical Report

Keywords:

Medicine Erythropoietin Myelodysplastic syndromes Anemia Internal medicine Gastroenterology Bone marrow Blood transfusion International Prognostic Scoring System Surgery

Metrics

Cited By

2.07

FWCI (Field Weighted Citation Impact)

Refs

0.86

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Acute Myeloid Leukemia Research

Health Sciences → Medicine → Hematology

Hemoglobinopathies and Related Disorders

Health Sciences → Medicine → Genetics

Erythropoietin and Anemia Treatment

Health Sciences → Medicine → Hematology

Treatment of anemia in low risk myelodysplastic syndromes with granulocyte–macrophage colony-stimulating factor plus recombinant human erythropoietin

Metrics

Citation History

Topics

Related Documents

Recombinant human granulocyte‐macrophage colony‐stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes

Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes

Recombinant human granulocyte‐macrophage colony‐stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes

Treatment of Myelodysplastic Syndromes with Recombinant Human Granulocyte Colony-Stimulating Factor

Sequential Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor and Human Erythropoietin for Treatment of Myelodysplastic Syndromes